Sérologie

SAPRIS-SERO est une étude qui vise à estimer la séroprévalence de l’infection par le SRAS-CoV-2 dans les cohortes épidémiologiques Constances, E3-E4N, NutriNet-Santé et Elfe-Epipage2 en France.

Rejoignez l’étude COVonco et contribuez a comprendre mieux l’impact de la COVID-19 dans l’oncologie.

Le projet EpiCOV vise à fournir une cartographie globale et scientifiquement fiable du statut immunitaire de la population en France à travers des tests sérologiques et des questionnaires.

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19 patients

This study aims to estimate the prevalence of antibodies against SARS-CoV-2 and help improve the prediction of infectious diseases and increase biosecurity in the Principality of Andorra.

Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.

The COVICAT study aims to evaluate the evolution of the incidence of SARS-CoV-2 coronavirus infection in the Catalan population over a 12-month period.

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.

This cross-sectional study estimates SARS-CoV-2 IgG antibody seroprevalence in the community in England using self-administered LFIAs.

This study assesses whether LFIAs should be used as a self-administered test among key workers or whether better performance is obtained if they attend a central clinic facility, e.g. for blood draw.

This COVID-19 study aims to evaluate the acceptability and usability of in-home self-testing for SARS-CoV-2 antibodies.